Note 3 - Intangible Assets

12 Months Ended

Jun. 30, 2016

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

3.     

Intangible Assets

Intangible assets consist of the following based on the Company’s determination of the fair value of identifiable assets acquired:

	June 30, 2016
	Weighted Average Amortization Period (in Years)		Gross Carrying Amount		Accumulated Amortization		Net
Trade names		7	$	29	$	10	$	19
Licenses		7		462		157		305
Customer relationships		3		424		335		89
Device registration		7		86		49		37
Covenants not to compete		5		955		454		501
Amortizable intangible assets				1,956		1,005		951
Clinical protocols				19,870		--		19,870
Total			$	21,826	$	1,005	$	20,821

	June 30, 2015
	Weighted Average Amortization Period (in Years)		Gross Carrying Amount		Accumulated Amortization		Net
Trade names		7	$	30	$	6	$	24
Licenses		7		490		96		394
Customer relationships		3		449		206		243
Device registration		7		92		20		72
Covenants not to compete		5		955		263		692
Amortizable intangible assets				2,016		591		1,425
Clinical protocols				19,870		--		19,870
Total			$	21,886	$	591	$	21,295

The change in the gross carrying amount is due to foreign currency exchange fluctuations. Amortization of intangible assets was $438 and $458 for the years ended June 30, 2016 and 2015. Clinical protocols have not yet been introduced to the market place and are therefore not yet subject to amortization. The Company’s estimated future amortization expense for subsequent years are as follows:

Year Ended June 30,
2017	$	358
2018		269
2019		197
2020		78
2021		49
Total	$	951